An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer ...

According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an infectious disease specialist before changing course.

– Scientists continuing to advance critical research on mechanisms of immune evasion exemplified by emerging SARS-CoV-2 variants – – Study identifies the N-terminal domain of the SARS-CoV-2 spike ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential ...

– Virtual R&D Day webcast scheduled for today, Wednesday, April 27, at 12:00 pm ET / 9:00 am PT – SAN FRANCISCO, April 27, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today ...

In January 2026, Vir Biotechnology reported new positive data from its ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta, where combination therapy with investigational agents tobevibart and ...

– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector – – Long-standing partnership further ...

Vir Biotechnology (NASDAQ:VIR) shares hit a new 52-week low Friday after BofA Securities downgraded its rating of the stock to neutral, citing limited near-term upside. Shares of Vir were down 6% at ...

Vir Biotechnology is narrowing its focus. Sitting on $1.9 billion, the infectious disease specialist has decided to stop work on its innate immunity small-molecule platform as part of its efforts to ...

– Study identifies the N-terminal domain of the SARS-CoV-2 spike protein as a target of potent neutralizing antibodies, but a target that can vary – – Separate research results published in Cell ...